Longevity News
The latest longevity research, curated from leading sources and analyzed through the EDGE Framework.
The latest longevity research, curated from leading sources and analyzed through the EDGE Framework.
XellSmart's off-the-shelf cell therapy XS411 met primary safety and tolerability endpoints in a nine-participant Phase I dose-escalation study in moderate-to-advanced Parkinson's disease, with no dose-limiting toxicities, no graft-induced dyskinesia and no aberrant cellular overgrowth on MRI. The company reports OFF-state MDS-UPDRS Part III improvements exceeding 30 points at six months and more than five additional hours of good ON time per day, with 18F-DOPA PET uptake at transplant sites consistent with graft survival and restored dopamine synthesis. A randomized multicenter Phase II trial in China has enrolled 30 participants.
BodySpec has opened a retail DEXA scanning location in Oakland offering roughly 12-minute body composition scans for under $60, reporting fat mass, visceral fat, lean muscle and bone density. The company positions the service against the rapid uptake of GLP-1 receptor agonists, citing evidence that 25 to 40 percent of weight lost on these drugs can be lean tissue. Muscle and bone mass are established predictors of functional independence and mortality risk, yet have historically been measured only inside clinical settings.
VectorY has expanded its Phase 1/2 PIONEER-ALS trial of VTx-002 from 12 to 36 participants before any efficacy data is available, citing rapid enrollment and site activation. VTx-002 is a vectorized antibody designed to produce sustained antibody expression within the central nervous system against TDP-43, the protein that aggregates abnormally in up to 97% of ALS cases. The open-label, placebo-free design means the larger cohort increases biomarker and functional observations without establishing clinical benefit.
A Censuswide survey of 1,000 UK dieters, commissioned by nutrition brand PortionIQ, found that 29% of those using GLP-1 medications for two years or more lacked confidence in their knowledge of essential nutrients, compared with 12% of those in their first month. Only 57% of long-term users believed they were meeting their nutrient needs, against 81% of new users. With appetite suppression reducing total intake, nutrient density and protein adequacy become determinants of whether weight loss preserves or erodes lean mass and metabolic function.
Jupiter Neurosciences has dosed the first patient in RESET, a 30-person Phase 2a trial of JOTROL, a micellar trans-resveratrol formulation, in Parkinson's disease. The study is powered for safety, tolerability and pharmacokinetics — including cerebrospinal fluid levels — with exploratory biomarkers covering energy metabolism and inflammation, not efficacy. The same announcement disclosed that the company has engaged an adviser to evaluate a sale, licensing or other strategic transaction.
John Beard, who led the WHO's World Report on Ageing and Health, argues that function — not diagnosis count — is the more accurate measure of how a person is aging. Intrinsic capacity assesses five domains: cognition, mobility, psychological resilience, sensory function and vitality, and can be tracked incrementally from midlife rather than waiting decades for disease endpoints. Cohort data from England and China indicate newer generations reach a higher functional peak rather than declining more slowly, suggesting interventions can raise the ceiling, not only slow the descent.
Elysium has introduced Balance, a formulation combining its NAD+ precursor product Basis with S-equol and ergothioneine, positioned for perimenopausal and menopausal symptom relief alongside longer-term postmenopausal health. The company reports that an open-label pilot of Basis showed a significant increase in the estradiol-to-estrone ratio with reductions in hot flashes, disrupted sleep and bloating; a larger randomized placebo-controlled trial is planned. The estradiol-to-estrone ratio is an emerging marker of reproductive aging, making it a measurable target rather than a symptom-only endpoint.
In aging mice, bone marrow fat cells secrete DPP4 and other factors that activate the cGAS–STING pathway in marrow macrophages, producing chronic inflammatory signaling that suppresses bone formation and lowers NAD⁺ in osteoblast progenitors. Silencing STING specifically in macrophages between 12 and 18 months preserved bone density and architecture, increased new bone deposition, and reduced marrow fat accumulation. The work positions innate immune sensing of displaced DNA as an upstream driver of age-related skeletal decline rather than a bystander.
Human tonsil-derived fibroblasts normally support B cell activation and expansion, but once pushed into a senescent state they block B cell proliferation while leaving early activation intact. The arrested B cells fail to complete the metabolic switch to glycolysis and synthesise almost no new protein, with direct cell–cell contact proving more inhibitory than secreted factors alone. The work identifies the lymphoid stromal niche, rather than B cells themselves, as a limiting factor in age-related decline of antibody responses.
Mighty Therapeutics and the University of Washington received $1 million as a Milestone 2 Awardee in the XPRIZE Healthspan competition for pilot work on elamipretide, a peptide that binds cardiolipin to support mitochondrial structure and function. The pilot results have not been disclosed; the team describes them as feasibility data intended to inform a randomized, placebo-controlled trial of muscle, cognitive and immune function in older adults. Elamipretide already holds FDA approval for Barth syndrome, making it one of the few mitochondria-directed therapies with a regulatory track record.
In a mouse model expressing progerin exclusively in cardiomyocytes, loss of the m6A methyltransferases METTL3 and METTL14 was sufficient to produce myocardial fibrosis, hypertrophy, and progressive functional decline. Reduced m6A writer activity suppressed the calcium-handling transcript Casq2 while raising senescence and type I interferon transcripts, and cardiomyocyte-targeted restoration of METTL14 partially reversed the pathological remodeling.
A 12-week randomized, double-blind, vehicle-controlled trial of RLX-201, the active compound in Re-Q Longevity Face Serum, has been published in the Journal of Cosmetic Dermatology. Across 47 women aged 35 to 65 with moderate-to-severe photoaging, the company reports improvements in investigator-assessed firmness and cheek wrinkles of 21% from baseline at Week 12, with instrumented elastometry indicating improved viscoelastic properties from Week 8 onward and no adverse events in either arm.